HUP0402028A2 - Telítetlen 1-amino-alkilciklohexán-származékok az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents
Telítetlen 1-amino-alkilciklohexán-származékok az ezeket tartalmazó gyógyászati készítmények és alkalmazásukInfo
- Publication number
- HUP0402028A2 HUP0402028A2 HU0402028A HUP0402028A HUP0402028A2 HU P0402028 A2 HUP0402028 A2 HU P0402028A2 HU 0402028 A HU0402028 A HU 0402028A HU P0402028 A HUP0402028 A HU P0402028A HU P0402028 A2 HUP0402028 A2 HU P0402028A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkenyl
- alkyl
- independently
- cyclohexa
- diene
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 229940123859 Nicotinic receptor antagonist Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000003976 azacycloalkanes Chemical class 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 abstract 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000285 glutaminergic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 239000003367 nicotinic antagonist Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000002829 nitrogen Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1
- 230000002295 serotoninergic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/25—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek és optikaiizomerjeik és gyógyászatilag elfogadható savaddíciós vagy bázissalalkotott addíciós sóik ahol a képletben R* jelentése -(A)n-(CR1R2)m-NR3R4, n+m=0, 1 vagy 2, A jelentése alkil-, alkenil- vagyalkinilcsoport, R1 és R2 jelentése egymástól függetlenül hidrogénatom,alkil-, alkenil- vagy alkinilcsoport, R3 és R9 jelentése egymástólfüggetlenül hidrogénatom, alkil-, alkenil- vagy alkinilcsoport, vagyegyütt alkilén- vagy alkeniléncsoportot képeznek, vagy anitrogénatommal együtt alkenilcsoporttal szubsztituált azacikloalkán-vagy azacikloalkén-csoportot alkotnak, R5 jelentése alkil-, alkenil-vagy alkinilcsoport, vagy R5 azzal a szénatommal, amelyhez kapcsolódikés egy szomszédos szénatommal kettős kötést alkot, Rp, Rq, Rr és Rsjelentése egymástól függetlenül hidrogénatom, alkil-, alkenil- vagyalkinilcsoport, vagy Rp, Rq, Rr vagy Rs egymástól függetlenül azzal aszénatommal, amelyhez kapcsolódik és egy szomszédos szénatommal kettőskötést alkot, vagy Rp, Rq, Rr és Rs egymástól függetlenül kettőskötést alkothat azzal az U vagy Y jelű molekularésszel, amelyhezkapcsolódik, azzal a megkötéssel, hogy U-V-W-X-Y-Z az alábbiakvalamelyike: ciklohexán, ciklohex-2-én, ciklohex-3-én, ciklohexa-l,4-dién, ciklohexa-l,5-dién, ciklohexa-2,4-dién és ciklohexa-2,5-dién, ésazzal a megkötéssel, hogy Rp és Rq közül legalább az egyik jelentésehidrogénatomtól eltérő és Rr és Rs közül legalább az egyik jelentésehidrogénatomtól eltérő, és azzal a megkötéssel, hogy ha U-Z jelentéseciklohexán, akkor -(A)n-(CR1R2)m-, R3, R4, R5, Rp, Rq, Rr és Rs közüllegalább az egyik alkenil- vagy alkinilcsoport. A találmány szerintivegyületek NMDA, 5-HT3 és nikotinreceptor antagonista hatássalrendelkeznek, így alkalmasak glutaminerg, szerotoninerg és nikotinostranszmisszió zavarát magában foglaló központi idegrendszerirendellenességek kezelésére, immunmodulátor rendellenességekkezelésére és fertőző betegségek kezelésére is. A találmány tárgyátképezik továbbá a vegyületeket tartalmazó gyógyászati készítmények ésalkalmazásuk is. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35097401P | 2001-11-07 | 2001-11-07 | |
US33785801P | 2001-11-08 | 2001-11-08 | |
PCT/GB2002/005038 WO2003040084A1 (en) | 2001-11-07 | 2002-11-07 | Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0402028A2 true HUP0402028A2 (hu) | 2005-01-28 |
HUP0402028A3 HUP0402028A3 (en) | 2008-03-28 |
Family
ID=26990903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402028A HUP0402028A3 (en) | 2001-11-07 | 2002-11-07 | Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US6828462B2 (hu) |
EP (1) | EP1442008A1 (hu) |
JP (1) | JP2005508381A (hu) |
KR (1) | KR100655975B1 (hu) |
CN (1) | CN100390131C (hu) |
AU (1) | AU2002337389B2 (hu) |
CA (1) | CA2465738C (hu) |
CO (1) | CO5570696A2 (hu) |
EA (1) | EA010177B1 (hu) |
GE (1) | GEP20053714B (hu) |
HK (1) | HK1075037A1 (hu) |
HU (1) | HUP0402028A3 (hu) |
IL (1) | IL161801A0 (hu) |
MX (1) | MXPA04004412A (hu) |
NO (1) | NO20042338L (hu) |
PL (1) | PL370245A1 (hu) |
WO (1) | WO2003040084A1 (hu) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW593223B (en) * | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
WO2005009421A2 (en) * | 2003-07-28 | 2005-02-03 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
CN101389315A (zh) * | 2004-06-17 | 2009-03-18 | 莫茨药物股份两合公司 | 美金刚口服剂型即释制剂 |
US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
WO2008103421A1 (en) * | 2007-02-21 | 2008-08-28 | Ssv Therapeutics, Inc. | Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids |
EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
JP5833922B2 (ja) | 2008-08-12 | 2015-12-16 | ジンファンデル ファーマシューティカルズ インコーポレイテッド | 疾患危険因子を同定する方法 |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
EP2665479B1 (en) | 2011-01-10 | 2019-06-26 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
US20150182546A1 (en) * | 2013-03-15 | 2015-07-02 | Mitochondrial Concepts Llc | Therapeutic agent for enhancing mitochondrial function |
CA3049800A1 (en) | 2017-01-10 | 2018-07-19 | Owen-Barry Pharmaceuticals Inc. | Anticonvulsant compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267366A (en) * | 1977-12-14 | 1981-05-12 | Scm Corporation | Cyclic terpenoid amines, their preparation and uses |
CZ293248B6 (cs) * | 1997-06-30 | 2004-03-17 | Merz Pharma Gmbh & Co. Kgaa | 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi |
US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
-
2002
- 2002-11-06 US US10/288,819 patent/US6828462B2/en not_active Expired - Fee Related
- 2002-11-07 HU HU0402028A patent/HUP0402028A3/hu unknown
- 2002-11-07 IL IL16180102A patent/IL161801A0/xx unknown
- 2002-11-07 GE GE5600A patent/GEP20053714B/en unknown
- 2002-11-07 PL PL02370245A patent/PL370245A1/xx not_active Application Discontinuation
- 2002-11-07 EP EP02772631A patent/EP1442008A1/en not_active Withdrawn
- 2002-11-07 JP JP2003542132A patent/JP2005508381A/ja active Pending
- 2002-11-07 WO PCT/GB2002/005038 patent/WO2003040084A1/en active IP Right Grant
- 2002-11-07 EA EA200400637A patent/EA010177B1/ru not_active IP Right Cessation
- 2002-11-07 MX MXPA04004412A patent/MXPA04004412A/es active IP Right Grant
- 2002-11-07 CA CA002465738A patent/CA2465738C/en not_active Expired - Fee Related
- 2002-11-07 AU AU2002337389A patent/AU2002337389B2/en not_active Ceased
- 2002-11-07 KR KR1020047006901A patent/KR100655975B1/ko not_active IP Right Cessation
- 2002-11-07 CN CNB02824530XA patent/CN100390131C/zh not_active Expired - Fee Related
-
2004
- 2004-05-06 CO CO04041831A patent/CO5570696A2/es not_active Application Discontinuation
- 2004-06-04 NO NO20042338A patent/NO20042338L/no not_active Application Discontinuation
-
2005
- 2005-08-22 HK HK05107277.4A patent/HK1075037A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20050044354A (ko) | 2005-05-12 |
JP2005508381A (ja) | 2005-03-31 |
GEP20053714B (en) | 2005-12-26 |
CN1602292A (zh) | 2005-03-30 |
CA2465738C (en) | 2009-01-20 |
PL370245A1 (en) | 2005-05-16 |
CO5570696A2 (es) | 2005-10-31 |
NO20042338L (no) | 2004-07-21 |
MXPA04004412A (es) | 2005-05-16 |
HK1075037A1 (en) | 2005-12-02 |
HUP0402028A3 (en) | 2008-03-28 |
WO2003040084A1 (en) | 2003-05-15 |
EA200400637A1 (ru) | 2004-10-28 |
EA010177B1 (ru) | 2008-06-30 |
IL161801A0 (en) | 2005-11-20 |
US6828462B2 (en) | 2004-12-07 |
US20030166634A1 (en) | 2003-09-04 |
CN100390131C (zh) | 2008-05-28 |
EP1442008A1 (en) | 2004-08-04 |
CA2465738A1 (en) | 2003-05-15 |
KR100655975B1 (ko) | 2006-12-08 |
AU2002337389B2 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0402028A2 (hu) | Telítetlen 1-amino-alkilciklohexán-származékok az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP9801887A2 (hu) | CCR-3 receptor antagonista hatású gyűrűs aminszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0100266A2 (hu) | NMDA-receptor-antagonista hatású 1-aminoalkilciklohexánszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és előállításaik | |
AR036874A1 (es) | Derivados de fenetanolina, procedimiento de preparacion, uso en la fabricacion de medicamentos para enfermedades respiratorias | |
AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
HUP0402191A2 (hu) | Humán metabotrop glutamát receptor antagonista aktivitással rendelkező acetilénszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
SE0104334D0 (sv) | Therapeutic agents | |
HUP0400684A2 (hu) | 5-Hidroxitriptamin-6-ligandumként használható heterociklilindazol- és -azaindazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0500870A2 (hu) | Nitrogéntartalmú heterociklusos melanokortin receptor ligandumok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303084A2 (hu) | Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
PA8472301A1 (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
HUP0400343A2 (hu) | Ciklopropil-indol-származékok mint szelektív szerotonin-újrafelvétel inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
PA8550201A1 (es) | Analogos de prostaglandina | |
HUP0101281A2 (hu) | Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0500201A2 (hu) | Policiklusos vegyületek, mint potenciális alfa2-adrenoceptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |